Sihuan Pharmaceutical Holdings Group Ltd. disclosed a next-day return confirming the repurchase of 10.00 million ordinary shares on 18 May 2026. The on-exchange purchases were executed at prices between HKD 1.05 and HKD 1.08, translating to a volume-weighted average cost of HKD 1.0685 per share and a total cash outlay of HKD 10.69 million.

Following the transaction, the company’s issued shares (excluding treasury shares) declined 0.11% to 9.13 billion, while treasury shares increased to 204.01 million. Total outstanding shares remain unchanged at 9.33 billion.

The buyback forms part of a mandate approved on 6 June 2025 that authorises the repurchase of up to 921.36 million shares. Cumulative repurchases under this mandate now stand at 87.60 million shares, representing 0.95% of the issued share count at the time the mandate was granted.

In accordance with Hong Kong listing rules, Sihuan Pharm is subject to a moratorium on issuing new shares or disposing of treasury shares until 17 June 2026.